MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-12-2026
Xenetic Biosciences Cash and Cash Equivalents 2011-2026 | XBIO
Annual Cash and Cash Equivalents Xenetic Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.88 M | 6.17 M | 8.98 M | 13.1 M | 18.2 M | 11.5 M | 10.4 M | 572 K | 5.53 M | 4.05 M | 132 K | 2.51 M | 4.84 M | 11.1 M | 17.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.2 M | 132 K | 8.14 M |
Quarterly Cash and Cash Equivalents Xenetic Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.12 M | 4.78 M | 5.16 M | 6.17 M | 6.84 M | 7.3 M | 7.82 M | 8.98 M | 9.78 M | 10.7 M | 12 M | 13.1 M | 13.8 M | 14.9 M | 16.2 M | 18.2 M | 19.7 M | 9.28 M | 10 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 572 K | 572 K | 572 K | 572 K | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 4.05 M | 4.05 M | 4.05 M | 4.05 M | 132 K | 132 K | 132 K | 132 K | 2.51 M | 2.51 M | 2.51 M | 2.51 M | 4.84 M | 4.84 M | 4.84 M | 4.84 M | 11.1 M | 32 K | 32 K | 32 K | 17.1 M | 10 K | 10 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.7 M | 10 K | 6.65 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Frequency Therapeutics
FREQ
|
21.8 M | - | - | $ 528 M | USA |
 |
argenx SE
ARGX
|
1.5 B | $ 700.45 | -1.19 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Grifols, S.A.
GRFS
|
980 M | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
ADC Therapeutics SA
ADCT
|
326 M | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
BioCardia
BCDA
|
1.1 M | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
72.9 M | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
70.5 M | - | - | $ 521 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Certara
CERT
|
189 M | $ 6.67 | 1.6 % | $ 1.07 B | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
187 K | - | -2.5 % | $ 5.88 M | USA |